SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D/A8 (Amendment No. 8)*
Under the Securities Exchange Act of 1934
LIGAND PHARMACEUTICALS INCORPORATED
--------------------------------------------------------------------------------
(Name of Issuer)
Common Stock, $0.001 par value
--------------------------------------------------------------------------------
(Title of Class of Securities)
53220K 20 7
--------------------------------------------------------------------------------
(CUSIP Number)
William F. Daniel
Elan Corporation, plc
Lincoln House
Lincoln Place
Dublin 2, Ireland
(353) 1-709-4000
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
(Name, Address and Telephone Number of Person Authorized to Receive
Notices and Communications)
July 11, 2003
--------------------------------------------------------------------------------
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition which is the subject of this Schedule 13D, and is filing this
schedule because of ss.ss. 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the
following box / /.
NOTE: Schedules filed in paper format shall include a signed original and five
copies of the schedule, including all exhibits. See ss. 240.13d-7 for other
parties to whom copies are to be sent.
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
SCHEDULE 13D
--------------------------------------------------------------------------------
CUSIP No. 53220K 20 7
--------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
Elan Corporation, plc
--------------------------------------------------------------------------------
I.R.S. Employer Identification No.: NA
--------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) / /
(b) / /
N/A
--------------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------------
4 SOURCE OF FUNDS
WC
--------------------------------------------------------------------------------
5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEMS 2(d) or 2(e) N/A
--------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Ireland
--------------------------------------------------------------------------------
7 SOLE VOTING POWER
NUMBER OF None
SHARES _____________________________________________
BENEFICIALLY 8 SHARED VOTING POWER
OWNED BY
EACH None
REPORTING _____________________________________________
PERSON WITH 9 SOLE DISPOSITIVE POWER
None
______________________________________________
10 SHARED DISPOSITIVE POWER
None
--------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
None
--------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES
--------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
N.A.
--------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON
CO
--------------------------------------------------------------------------------
Item 1. Security and Issuer.
------ -------------------
This Amendment No. 8 amends the Schedule 13D filed with the Securities
and Exchange Commission (the "Commission") on January 6, 1999, as amended by the
Schedule 13D/A1 filed with the Commission on July 27, 1999, as amended by the
Schedule 13D/A2 filed with the Commission on July 29, 1999, as amended by the
Schedule 13D/A3 filed with the Commission on September 10, 1999, as amended by
the Schedule 13D/A4 filed with the Commission on December 17, 1999, as amended
by Schedule 13D/A5 filed with the Commission September 11, 2000, as amended by
Schedule 13D/A6 filed with the Commission on March 22, 2002, as amended by
Schedule 13D/A7 filed with the Commission on June 17, 2003 (as so amended, this
"Schedule 13D"), with respect to the Common Stock, $0.001 par value per share
("Common Stock"), of Ligand Pharmaceuticals Incorporated (the "Issuer"), a
Delaware corporation, whose principal executive offices are located at 10275
Science Center Drive, San Diego, California 92121-1117.
Item 5. Interest in Securities of the Issuer.
------ ------------------------------------
Item 5 (a) of the Schedule 13D is restated in its entirety as follows:
(a) Elan is no longer the beneficial owner of any shares of Common
Stock.
(c) Elan sold 5,835,771 shares of Common Stock on July 11, 2003 at a
price of $11.50 per share in a transaction exempt from registration under the
Securities Act of 1933, as amended.
(e) On July 11, 2003, Elan ceased to be the beneficial owner of more
than five percent of the class of securities.
-1-
Signature
The undersigned certifies that, after reasonable inquiry and to the
best of its knowledge and belief, the information set forth in this statement is
true, complete and correct.
July 21, 2003
ELAN CORPORATION, PLC
By: /s/ Shane M. Cooke
------------------------------------
Name: Shane M. Cooke
Title: Executive Vice President and
Chief Financial Officer